Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regulatory News In Brief

This article was originally published in The Gray Sheet

Executive Summary

Abbott catheter recall: Abbott is recalling four lots of Powersail coronary dilation catheters--three from U.S. distribution and one from international distribution--following four complaints of damage to the distal shaft of the catheter, firm announced July 28. FDA is classifying the recall as Class I, the most serious category, according to the firm. The observed damage could cause the contrast material to leak, potentially causing clinical problems such as air embolism or myocardial infarction, Abbott says. Sales reps have instructed all customers to stop using the affected lots. Patients already successfully treated with Powersail coronary catheters are not affected by the recall

You may also be interested in...



FDA Will Review Safety Of Dental Amalgams In Light Of New Data

CDRH is willing to do some more number-crunching on its 2009 decision that mercury from dental amalgam is safe for all patients, in light of new data that most of the U.S. population may be exposed to higher levels of the toxin in their fillings than is acceptable, FDA officials said at a recent advisory panel meeting.

FDA Will Review Safety Of Dental Amalgams In Light Of New Data

CDRH is willing to do some more number-crunching on its 2009 decision that mercury from dental amalgam is safe for all patients, in light of new data that most of the U.S. population may be exposed to higher levels of the toxin in their fillings than is acceptable, FDA officials said at a recent advisory panel meeting.

Regulatory News In Brief

Fiscal 2012 budget cuts: White House Office of Management and Budget Director Peter Orszag and White House Chief of Staff Rahm Emanuel are directing federal agencies to find ways to cut their fiscal 2012 budgets by 5%, according to a June 8 1memo and budget 2guidance. Agencies should identify programs "that have the lowest impact on your agency's mission," the memo states. Fiscal 2012 budget submissions are due to OMB by Sept. 13. The Obama administration has pledged to freeze non-security discretionary spending through fiscal 2013

Related Content

Topics

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel